deploy: 5c151d2

index.html

@@ -368,6 +368,18 @@ <h3>JASN 2023</h3>
 								</ul>
 							</div>
 						</article>
+						<article>
+							<a data-fancybox data-src="images/gallery/pdfs/Kidney_Int_2022.pdf" data-type="pdf" href="" class="image">
+								<img src="../../images/gallery/thumbs/Kidney_Int_2022.jpg" alt="" />
+							</a>
+							<div class="caption">
+								<h3>Kidney Int 2022</h3>
+								<p>GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes</p>
+								<ul class="actions fixed">
+									<li><span class="button small">View PDF</span></li>
+								</ul>
+							</div>
+						</article>
 						<article>
 							<a data-fancybox data-src="images/gallery/pdfs/ndt-2023.pdf" data-type="pdf" href="" class="image">
 								<img src="../../images/gallery/thumbs/ndt-2023.jpg" alt="" />
@@ -392,6 +404,18 @@ <h3>Kidney Int 2023</h3>
 								</ul>
 							</div>
 						</article>
+						<article>
+							<a data-fancybox data-src="images/gallery/pdfs/Kidney_Int_2024.pdf" data-type="pdf" href="" class="image">
+								<img src="../../images/gallery/thumbs/Kidney_Int_2024.jpg" alt="" />
+							</a>
+							<div class="caption">
+								<h3>Kidney Int 2024</h3>
+								<p>A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes</p>
+								<ul class="actions fixed">
+									<li><span class="button small">View PDF</span></li>
+								</ul>
+							</div>
+						</article>
 					</div>
 					<br><br><br>
 					<!-- <div id="key-publications"></div> -->